Wall Street brokerages expect that Surgery Partners Inc (NASDAQ:SGRY) will post earnings of $0.12 per share for the current fiscal quarter, Zacks Investment Research reports. Two analysts have issued estimates for Surgery Partners’ earnings. The lowest EPS estimate is $0.01 and the highest is $0.22. Surgery Partners posted earnings of ($0.74) per share in the same quarter last year, which indicates a positive year-over-year growth rate of 116.2%. The business is expected to announce its next quarterly earnings results on Wednesday, March 11th.
On average, analysts expect that Surgery Partners will report full year earnings of ($0.88) per share for the current financial year, with EPS estimates ranging from ($0.98) to ($0.77). For the next year, analysts anticipate that the firm will post earnings of ($0.42) per share, with EPS estimates ranging from ($0.70) to ($0.14). Zacks Investment Research’s earnings per share averages are an average based on a survey of sell-side analysts that cover Surgery Partners.
Surgery Partners (NASDAQ:SGRY) last posted its quarterly earnings data on Tuesday, November 5th. The company reported ($0.28) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.34) by $0.06. The business had revenue of $452.00 million for the quarter, compared to analysts’ expectations of $452.30 million. Surgery Partners had a negative return on equity of 5.32% and a negative net margin of 11.26%. The business’s revenue was up 1.8% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.19) EPS.
A number of analysts have recently commented on SGRY shares. ValuEngine cut Surgery Partners from a “strong-buy” rating to a “buy” rating in a research report on Tuesday. BidaskClub cut Surgery Partners from a “strong-buy” rating to a “buy” rating in a research report on Friday. Citigroup boosted their price target on Surgery Partners from $13.00 to $20.00 and gave the stock a “buy” rating in a research report on Tuesday. Finally, Zacks Investment Research raised Surgery Partners from a “hold” rating to a “buy” rating and set a $16.00 price target on the stock in a research report on Saturday, December 7th. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus price target of $16.00.
Surgery Partners stock traded down $0.17 during trading hours on Friday, hitting $14.51. 231,555 shares of the stock traded hands, compared to its average volume of 307,874. The firm’s 50-day moving average price is $11.86 and its two-hundred day moving average price is $8.61. The company has a current ratio of 1.36, a quick ratio of 1.24 and a debt-to-equity ratio of 2.39. The company has a market cap of $733.93 million, a PE ratio of -5.92 and a beta of 2.68. Surgery Partners has a one year low of $5.38 and a one year high of $15.49.
Several institutional investors and hedge funds have recently modified their holdings of the company. Millennium Management LLC boosted its position in shares of Surgery Partners by 5,528.2% in the 3rd quarter. Millennium Management LLC now owns 652,631 shares of the company’s stock worth $4,819,000 after purchasing an additional 664,654 shares in the last quarter. Squarepoint Ops LLC lifted its position in Surgery Partners by 96.0% in the 3rd quarter. Squarepoint Ops LLC now owns 95,758 shares of the company’s stock valued at $707,000 after acquiring an additional 46,891 shares in the last quarter. Barclays PLC lifted its position in Surgery Partners by 21.6% in the 3rd quarter. Barclays PLC now owns 19,294 shares of the company’s stock valued at $143,000 after acquiring an additional 3,432 shares in the last quarter. State Street Corp lifted its position in Surgery Partners by 20.0% in the 3rd quarter. State Street Corp now owns 448,935 shares of the company’s stock valued at $3,315,000 after acquiring an additional 74,930 shares in the last quarter. Finally, Rhumbline Advisers lifted its position in Surgery Partners by 8.7% in the 3rd quarter. Rhumbline Advisers now owns 34,402 shares of the company’s stock valued at $254,000 after acquiring an additional 2,763 shares in the last quarter. 96.05% of the stock is currently owned by hedge funds and other institutional investors.
Surgery Partners Company Profile
Surgery Partners, Inc, through its subsidiaries, owns and operates a network of surgical facilities and related services in the United States. The company operates through three segments: Surgical Facility Services, Ancillary Services, and Optical Services. Its surgical facilities comprise ambulatory surgery centers and surgical hospitals that offer non-emergency surgical procedures in various specialties, including gastroenterology, general surgery, ophthalmology, orthopedics, and pain management.
Read More: Dividend Aristocrat Index
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Surgery Partners Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Surgery Partners and related companies with MarketBeat.com's FREE daily email newsletter.